A new vaccine against HPV (human papilloma virus) may enter into medical practice in early 2014. Its manufacturer, Merck & Co, hopes that the Food and Drug Administration will approve the drug to the end of this year. Merck’s drug Gardasil is used to immunize women against HPV since 2006.
It cures four types of virus (6, 11, 16 and 18) causing 70% of cervical cancers. The new nine-valent vaccine V503 works against five types of HPV – 31, 33, 45, 52 and 58. So protection is achieved by 90% of malignant tumors provoked by HPV. In the hands of Merck & Co are results of the third phase of the clinical trials of efficacy, safety, and immunogenicity of V503 in comparison with Gardasil. The vaccine was tested in women 16-26 years of age.
According to the report, V503 has an efficiency of 96.7% from the viewpoint of prevention of diseases of the cervix, vulva and vagina caused by 31, 33, 45, 52 and 58 types of HPV, and 97.1% efficacy against all 9 types of the virus. Merck & Co says that V503 has all the chances to get in vaccination plan instead of Gardasil. If the company receives approval then the profit of the vaccine may be more than one billion dollars.